HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · IEX Real-Time Price · USD
18.16
-0.83 (-4.37%)
At close: Apr 26, 2024, 4:00 PM
18.24
+0.08 (0.44%)
After-hours: Apr 26, 2024, 7:55 PM EDT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,988 employees on December 31, 2023. The number of employees decreased by 37 or -1.83% compared to the previous year.
Employees
1,988
Change (1Y)
-37
Growth (1Y)
-1.83%
Revenue / Employee
$421,529
Profits / Employee
$50,694
Market Cap
3.16B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,988 | -37 | -1.83% |
Dec 31, 2022 | 2,025 | 266 | 15.12% |
Dec 31, 2021 | 1,759 | 479 | 37.42% |
Dec 31, 2020 | 1,280 | 427 | 50.06% |
Dec 31, 2019 | 853 | 139 | 19.47% |
Dec 31, 2018 | 714 | 124 | 21.02% |
Dec 31, 2017 | 590 | 27 | 4.80% |
Dec 31, 2016 | 563 | 112 | 24.83% |
Dec 31, 2015 | 451 | 102 | 29.23% |
Dec 31, 2014 | 349 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fortrea Holdings | 19,000 |
Envista Holdings | 12,800 |
Evolent Health | 4,700 |
iRhythm Technologies | 2,000 |
Axonics | 797 |
ImmunityBio | 628 |
Iovance Biotherapeutics | 557 |
Axsome Therapeutics | 545 |
HCM News
- 2 days ago - HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - GlobeNewsWire
- 23 days ago - HUTCHMED Highlights Data to be Presented at AACR Congress 2024 - GlobeNewsWire
- 26 days ago - Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status - PRNewsWire
- 26 days ago - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status - GlobeNewsWire
- 4 weeks ago - HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - GlobeNewsWire
- 5 weeks ago - HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewsWire
- 2 months ago - HUTCHMED Reports 2023 Full Year Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session - GlobeNewsWire